The startup develops a plasma and chitosan platform technology for eye care, wound healing, and burn care, offering products such as eye drops, gels, ointments, and specialized dressings. This technology enables healthcare professionals to effectively treat a range of ocular and dermal conditions, enhancing patient recovery outcomes.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for ocular surface diseases, such as neurotrophic keratitis (NK) and dry eye disease (DED), often fail to provide adequate relief or address the underlying causes of impaired healing and corneal damage. Many of the 22 million dry eye patients in the US are not satisfied with current treatment options. Similarly, effective treatments are needed for hard-to-heal wounds, burns and ulcers.
Solution
ECI Therapeutics develops products that leverage a platform combining human platelet-rich plasma-derived growth factors with hyaluronic acid (HA) or chitosan to promote accelerated healing of epithelial disorders. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and mucoadhesive properties of HA or chitosan, provide both immediate relief and long-lasting therapeutic action. ECI's products range from liquid eye drops to gels, ointments, contact lenses, and specialized dressings. The company's initial focus is on ophthalmic indications, specifically neurotrophic keratitis (NK) and dry eye disease (DED), with plans to expand into wound care, burn treatment, and other mucosal membrane applications.
Target Audience
The primary target audience includes patients suffering from ocular surface diseases like neurotrophic keratitis (NK) and dry eye disease (DED), as well as individuals with wounds, burns, ulcers, and chronic mucosal membrane dryness.
Features
- Synergistic combination of platelet-rich plasma-derived growth factors and hyaluronic acid or chitosan
- Therapeutic formulation suitable for liquid eye drops, gels, ointments, contact lenses, and wound dressings
- Products designed to promote cell proliferation, tissue regeneration, and repair
- Mucoadhesive excipients to enhance delivery and improve consistency
- Orthogonal safety plan meeting all regulatory requirements, including pathogen inactivation and removal technologies
- Targeted therapeutic approach for neurotrophic keratitis (NK) by promoting nerve regeneration and corneal healing
- Potential for orphan drug status for NK treatment
- Scaffold creation using chitosan and incorporation of human plasma-derived growth factors for wound healing